Central Nervous System (CNS) Biomarkers Technologies and Global Markets Report - Growing Incidence and Financial Burden of Neurological Disorders - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Central Nervous System (CNS) Biomarkers: Technologies and Global Markets" report has been added to ResearchAndMarkets.com's offering.

The global CNS biomarker market was valued at $5.7 billion in 2022. The market is projected to reach $9.5 billion in 2027, growing at a CAGR of 10.8% during the forecast period. This aggressive growth rate will be driven by several factors, including the increase in public-private partnerships with government support, pressure to keep healthcare costs down, a growing elderly population, and the rapid advancement of the genomic and proteomic technologies that have impacted the CNS biomarker diagnostics area.

There is huge unmet need in the area of CNS diseases due to the lack of fast and sensitive diagnostic methods and effective treatments. CNS biomarkers are rapidly emerging as the mainstay in the identification of patients at risk, early diagnosis, follow-up of disease progression, and effectiveness of treatments in neurology, in particular for demyelinating diseases (such as multiple sclerosis), neurodegenerative diseases (such as Alzheimer's disease) or traumatic brain injury.

In order to expedite drug development for neurology diseases, it is important to identify novel biomarkers that enhance diagnostic and prognostic accuracy, improve the existing decision criteria for early diagnosis and risk stratification, assist in disease monitoring, and act as surrogate endpoints in experimental studies and clinical trials. Efforts are being directed to expand neurology research and develop platforms and methods that can provide deeper insights into brain biology and aid in further biomarker research. Several biomarkers that have been identified in the past decade are under investigation for their potential applications. Once these biomarkers are validated and subsequently enter into clinical and research applications, the CNS biomarkers market is expected to grow significantly.

This study provides a comprehensive analysis of CNS biomarkers on a global basis. Its aim is to provide a range of information, from detailed product analyses within disease subsegments to overall industry trends, in order to quantify and qualify the global CNS biomarkers market.

Current and projected product forecasts during the forecast period (2022 to 2027) are discussed. New products approved in 2021 and 2022 by the U.S. Food and Drug Administration (FDA), and those products expected to be approved within the forecast period are discussed. Market figures for 2022 are estimated, except where actual results have been reported.

Included in this report are forecasts by biomarker type, technology type, disease, application, and region from 2022 through 2027. The report also includes analysis of leading and emerging competitors in the current worldwide CNS biomarkers market. Profiles of manufacturers of leading products, as well as biotechnology companies with novel products in development, are analyzed to define the specific product strategies employed. This report also assesses companies poised to introduce products during the forecast period and discusses how these introductions will change the face of the competitive environment. The competitive environment is examined with a special focus on how new products and technologies are influencing the current standard of care.

The Report Includes

• An overview of the global market and technologies for central nervous system (CNS) biomarkers
• Estimation of the market size and analyses of market trends, with data from 2019 to 2021, estimates for 2022, and projections of compound annual growth rates (CAGRs) through 2027
• Explanation of market drivers, restraints and other forces impacting the global market
• Description of technologies such as genomics, proteomics, and imaging, and assessments of their advantages and disadvantages.
• Discussion of CNS disease segments, prevalence, and gaps in treatment for Alzheimer's disease, depression, Parkinson's disease, multiple sclerosis, and others
• Coverage of events like mergers & acquisitions, joint ventures, collaborations or partnerships, and other key market strategies
• Comprehensive company profiles of major players of the industry, including Abbott, Bio-Rad Laboratories Inc., Eisai Co. Ltd., Merck and Thermo Fisher Scientific Inc.

Key Attributes:

Key Topics Covered:

Chapter 1 Introduction

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

Chapter 4 Market Dynamics

4.1 Drivers

4.1.1 Growing Incidence and Financial Burden of Neurological Disorders

4.1.2 High Unmet Need in Neurodegenerative Disorders

4.1.3 Need to Reduce Drug Development Costs and Failures

4.1.4 Increasing Investment in Neuroscience

4.1.5 Developments in Analytical Technologies and Assay Methods

4.1.6 Support from Regulatory Agencies

4.2 Restraints

4.2.1 Technological Challenges

4.2.2 Regulatory and Reimbursement Challenges

Chapter 5 Market Breakdown by Disease

Chapter 6 Market Breakdown by Application

Chapter 7 Market Breakdown by Technology Type

Chapter 8 Market Breakdown by Biomarker Type

Chapter 9 Market Breakdown by Region

Chapter 10 Impact of Covid-19

Chapter 11 Competitive Landscape

Chapter 12 Emerging Products/Technologies in the Market

Chapter 13 Company Profiles

• Abbott Laboratories Ltd.
• Biomerieux S.A.
• Bio-Rad Laboratories Inc.
• C2N Diagnostics, LLC
• Diadem Spa
• Eisai Co. Ltd.
• Eli Lilly and Co.
• F. Hoffmann-La Roche AG
• H.U. Group Holdings Inc.
• Laboratory Corp. Of America (Labcorp)
• Merck KGaA
• PerkinElmer Inc.
• Quanterix Corp.
• Quest Diagnostics Inc.
• Shimadzu Corp.
• Siemens Healthineers AG
• Sysmex Corp.
• Thermo Fisher Scientific Inc.

For more information about this report visit https://www.researchandmarkets.com/r/lug68c

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470
For U.S./ CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900